Gilead Sciences (GILD) 101.82 $GILD
Most active Nasdaq-traded stocks
AP - 21 mins ago
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
SPLS: 14.24 (-0.19), MU: 36.07 (-0.03), TIBX: 24.00 (-0.03), GILD: 101.82 (+0.94), AMAT: 24.40 (-0.18), JBLU: 15.09 (+0.27), MSFT: 48.84 (+0.76), INTC: 37.46 (+0.03), AAPL: 115.49 (-0.44), CSCO: 27.77 (-0.18), RFMD: 15.53 (+0.52)
Final Glance: Biotechnology companies
AP - 21 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 101.82 (+0.94), AMGN: 166.55 (-1.52), CELG: 113.63 (-0.60)
Hot Drugmakers Build More Labs, Grab Space In Boston
at Investor's Business Daily - 1 hr 37 mins ago
The greater Boston area has seen an influx of some fast-growing biotechs like Biogen Idec (BIIB) that have been taking lab space, a trend that's driven down vacancy rates in a big way. That's under way while the the biotech sector is surging -- IBD's...
BIIB: 341.18 (-6.16), ARE: 88.12 (+1.73), GILD: 101.82 (+0.94), BAX: 73.57 (-0.16), PFE: 31.67 (-0.08), AMGN: 166.55 (-1.52), AGIO: 104.05 (+2.03)
Gilead Sciences: An Alpha Stock Through The Good And Bad Times
Michael Grogan - at Seeking Alpha - Thu Dec 04, 2:14PM CST
AGN: 213.71 (+1.74), BIIB: 341.18 (-6.16), GILD: 101.82 (+0.94), AMGN: 166.55 (-1.52), NVS: 95.77 (+0.11)
Midday Glance: Biotechnology companies
AP - Thu Dec 04, 12:49PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 101.82 (+0.94), AMGN: 166.55 (-1.52), CELG: 113.63 (-0.60)
Early Glance: Biotechnology companies
AP - Thu Dec 04, 10:07AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
GILD: 101.82 (+0.94), AMGN: 166.55 (-1.52), CELG: 113.63 (-0.60)
3 Cheap Growth Stocks You Can Buy Right Now
Sean Williams, The Motley Fool - Motley Fool - Thu Dec 04, 9:04AM CST
Source: Flickr user One Way Stock. With the stock market in nonstop rally mode over the past five years, an investor doesn't need to look far to uncover an overabundance of growth stocks. Unfortunately, not all growth stocks are created...
ARLP: 44.98 (-0.36), GILD: 101.82 (+0.94), LUV: 41.39 (+0.34)
1 Big FDA Decision I'm Watching This Month
Cheryl Swanson, The Motley Fool - Motley Fool - Thu Dec 04, 8:15AM CST
Biotech investing is very risky -- failures outnumber successes. Pundits like to joke that small and mid-sized biotechs should come with a black box label: WARNING: A wrong decision can cost you 90% of your investment. On the other hand, what other...
GILD: 101.82 (+0.94), INCY: 74.12 (-0.54), LLY: 72.38 (+1.25), ABBV: 69.57 (+1.07), ENTA: 46.25 (+0.03), NVS: 95.77 (+0.11)
Why Biotech Stocks Don't Pay Dividends
Todd Campbell, The Motley Fool - Motley Fool - Thu Dec 04, 8:13AM CST
Dividend paying stocks are a staple in market-beating investment portfolios, but dividend investors don't have very many options when it comes to investing in the biotechnology sector. Out of the largest biotechnology stocks, only Amgen has made...
JNJ: 107.56 (-0.16), GILD: 101.82 (+0.94), AZN: 73.94 (+0.12), AMGN: 166.55 (-1.52)
A Practical Approach To Tech Investing
Franklin Templeton Investments - Seeking Alpha - Thu Dec 04, 8:00AM CST
Matt Moberg Vice President/Research Analyst Portfolio Manager, Franklin DynaTech Fund Franklin Equity Group® With the nervousness over geopolitical concerns, including a slowdown in the eurozone, ISIS in the Middle East and the US mid-term...
GILD: 101.82 (+0.94), FB: 75.24 (+0.36), BABA: 109.17 (-1.47)
Reveal Earnings Forecast for Gilead Sciences, Kinder Morgan, JD.Com, Sirius XM, Apple, and Plug Power
PR Newswire - Thu Dec 04, 7:45AM CST
EarningForecast.com has issued earnings forecast research with special focus on financial performance of the following stocks: Gilead Sciences (NASDAQ:GILD), Kinder Morgan (NYSE:KMI), JD.Com (NASDAQ:JD), Sirius XM (NASDAQ:SIRI), Apple (NASDAQ:AAPL), and Plug Power (NASDAQ
LUG).
KMI: 41.46 (-0.37), GILD: 101.82 (+0.94), PLUG: 3.70 (+0.20), JD: 24.47 (-0.13), AAPL: 115.49 (-0.44), SIRI: 3.58 (-0.02)
U.S. Veterans get Sovaldi for $594/pill
Seeking Alpha - at Seeking Alpha - Thu Dec 04, 7:43AM CST
GILD: 101.82 (+0.94), ABBV: 69.57 (+1.07)
Johnson & Johnson Bought Alios for Hepatitis C
Cheryl Swanson, The Motley Fool - Motley Fool - Thu Dec 04, 7:21AM CST
Don't look now, but Johnson & Johnson last month bought up South San Francisco-based Alios BioPharma for a cool $1.75 billion . So what's afoot? What is the health care giant really after with this deal? Alios is a clinical stage...
JNJ: 107.56 (-0.16), GILD: 101.82 (+0.94)
Cramer's Mad Money - PVH Fits Well At A Discount (12/3/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Thu Dec 04, 5:04AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday December 3. CEO interview: Manny Chirico, PVH (NYSE: PVH ). Other stock mentioned: J.C. Penney (NYSE: JCP ) PVH ( PVH ) delivered an 8 cent earnings...
BIIB: 341.18 (-6.16), HON: 99.26 (-0.71), UTX: 111.21 (+0.22), KMB: 114.60 (-0.10), INTC: 37.46 (+0.03), PVH: 122.68 (-1.72), SLB: 87.43 (+0.67), PEP: 97.75 (-0.57), GWPH: 74.55 (-1.46), EOG: 93.00 (+1.20), REGN: 423.21 (-1.20), CSCO: 27.77 (-0.18), MU: 36.07 (-0.03), SWKS: 69.75 (+3.08), HAL: 40.74 (-0.01), SN: 9.06 (-0.88), BMY: 58.89 (-0.14), BA: 131.32 (-0.65), HPQ: 39.07 (+0.02), CELG: 113.63 (-0.60), ZTS: 44.00 (-0.88), GILD: 101.82 (+0.94), TXN: 55.41 (-0.21), JCP: 6.73 (-0.46), PG: 90.58 (+0.58), PAY: 35.96 (+0.15), SWHC: 9.41 (-0.10)
Jim Cramer's 'Mad Money' Recap: Cyclical Stocks Are Fund Manager Picks Now
at The Street - Wed Dec 03, 7:36PM CST
Staple stocks like PepsiCo and Procter & Gamble were leaders but now fund managers are turning to the Caterpillars and Cummins of the world, Cramer says.
HK: 1.80 (-0.25), MAIN: 31.89 (+0.17), INTC: 37.46 (+0.03), SLB: 87.43 (+0.67), PVH: 122.68 (-1.72), HUM: 141.12 (-0.59), PEP: 97.75 (-0.57), AGN: 213.71 (+1.74), ECA: 14.97 (-0.51), SCTY: 52.37 (+0.63), CMI: 149.96 (-0.64), GWPH: 74.55 (-1.46), EOG: 93.00 (+1.20), EMC: 30.32 (+0.01), GOOGL: 542.58 (+5.61), CAT: 99.67 (-0.51), ZNGA: 2.53 (-0.01), CSCO: 27.77 (-0.18), SD: 2.35 (-0.13), CBI: 46.07 (-1.33), JOY: 51.50 (-0.72), MU: 36.07 (-0.03), ETN: 69.48 (-0.73), HAL: 40.74 (-0.01), SN: 9.06 (-0.88), BMY: 58.89 (-0.14), HPQ: 39.07 (+0.02), CELG: 113.63 (-0.60), PXD: 145.53 (-5.20), GILD: 101.82 (+0.94), PG: 90.58 (+0.58), AUY: 4.01 (-0.10), SNDK: 102.64 (-0.72)
Third Quarter Earnings Season In Review: Sector Winners And Losers, The Misleading 'Record' Beat Rate And The Outlook For Q4
Leigh Drogen - Seeking Alpha - Wed Dec 03, 4:50PM CST
On Monday, the third quarter earnings season will officially close out, with H&R Block (NYSE: HRB ) as the final S&P 500 company to report. The season is ending with impressive earnings growth of 11.7%, paired with revenue growth of 4.8%,...
KO: 43.50 (-0.30), JNJ: 107.56 (-0.16), AA: 17.24 (+0.03), GE: 26.09 (-0.29), AZO: 588.07 (-2.48), NKE: 99.05 (+0.55), GILD: 101.82 (+0.94), MCD: 95.66 (+0.16), XOM: 94.37 (-0.58), DG: 67.79 (+1.10), PVH: 122.68 (-1.72), HRB: 34.14 (-0.33)
Actelion submits MAA for pulmonary hypertension drug
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 2:36PM CST
MSTX: 0.45 (-0.02), GILD: 101.82 (+0.94), UTHR: 129.05 (-3.30), GSK: 45.89 (-0.82), ARNA: 4.14 (-0.06)
Gilead Sciences' (GILD) Management Presents at Piper Jaffray Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Wed Dec 03, 10:53AM CST
GILD: 101.82 (+0.94)
Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/pbx995/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Idiopathic Pulmonary Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AdAlta - AnaptysBio - Auspex Pharmaceuticals - BiOrion Technologies - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgeneration - Chong Kun Dang Pharmaceutical - Compugen - Corridor Pharmaceuticals - F. Hoffmann-La Roche - FibroGen - GenKyoTex - Gilead Sciences - GlaxoSmithKline - HanAll Biopharma - Histocell - ImmuneWorks - IntelGenx - InterMune - Kasiak Research - LTT Bio-Pharma - Lanthio Pharma - MSM Protein Technologies - MedImmune - Moerae Matrix - Pacific Therapeutics - Pharmaxis Limited - ProMetic Life Sciences For more information visit http://www.researchandmarkets.com/research/pbx995/idiopathic
BIIB: 341.18 (-6.16), GILD: 101.82 (+0.94), CGEN: 7.40 (+0.56), ASPX: 24.53 (-0.43), GSK: 45.89 (-0.82), BMY: 58.89 (-0.14)
Most active Nasdaq-traded stocks
AP - 21 mins ago
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
SPLS: 14.24 (-0.19), MU: 36.07 (-0.03), TIBX: 24.00 (-0.03), GILD: 101.82 (+0.94), AMAT: 24.40 (-0.18), JBLU: 15.09 (+0.27), MSFT: 48.84 (+0.76), INTC: 37.46 (+0.03), AAPL: 115.49 (-0.44), CSCO: 27.77 (-0.18), RFMD: 15.53 (+0.52)
Final Glance: Biotechnology companies
AP - 21 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 101.82 (+0.94), AMGN: 166.55 (-1.52), CELG: 113.63 (-0.60)
Hot Drugmakers Build More Labs, Grab Space In Boston
at Investor's Business Daily - 1 hr 37 mins ago
The greater Boston area has seen an influx of some fast-growing biotechs like Biogen Idec (BIIB) that have been taking lab space, a trend that's driven down vacancy rates in a big way. That's under way while the the biotech sector is surging -- IBD's...
BIIB: 341.18 (-6.16), ARE: 88.12 (+1.73), GILD: 101.82 (+0.94), BAX: 73.57 (-0.16), PFE: 31.67 (-0.08), AMGN: 166.55 (-1.52), AGIO: 104.05 (+2.03)
Gilead Sciences: An Alpha Stock Through The Good And Bad Times
Michael Grogan - at Seeking Alpha - Thu Dec 04, 2:14PM CST
AGN: 213.71 (+1.74), BIIB: 341.18 (-6.16), GILD: 101.82 (+0.94), AMGN: 166.55 (-1.52), NVS: 95.77 (+0.11)
Midday Glance: Biotechnology companies
AP - Thu Dec 04, 12:49PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 101.82 (+0.94), AMGN: 166.55 (-1.52), CELG: 113.63 (-0.60)
Early Glance: Biotechnology companies
AP - Thu Dec 04, 10:07AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
GILD: 101.82 (+0.94), AMGN: 166.55 (-1.52), CELG: 113.63 (-0.60)
3 Cheap Growth Stocks You Can Buy Right Now
Sean Williams, The Motley Fool - Motley Fool - Thu Dec 04, 9:04AM CST
Source: Flickr user One Way Stock. With the stock market in nonstop rally mode over the past five years, an investor doesn't need to look far to uncover an overabundance of growth stocks. Unfortunately, not all growth stocks are created...
ARLP: 44.98 (-0.36), GILD: 101.82 (+0.94), LUV: 41.39 (+0.34)
1 Big FDA Decision I'm Watching This Month
Cheryl Swanson, The Motley Fool - Motley Fool - Thu Dec 04, 8:15AM CST
Biotech investing is very risky -- failures outnumber successes. Pundits like to joke that small and mid-sized biotechs should come with a black box label: WARNING: A wrong decision can cost you 90% of your investment. On the other hand, what other...
GILD: 101.82 (+0.94), INCY: 74.12 (-0.54), LLY: 72.38 (+1.25), ABBV: 69.57 (+1.07), ENTA: 46.25 (+0.03), NVS: 95.77 (+0.11)
Why Biotech Stocks Don't Pay Dividends
Todd Campbell, The Motley Fool - Motley Fool - Thu Dec 04, 8:13AM CST
Dividend paying stocks are a staple in market-beating investment portfolios, but dividend investors don't have very many options when it comes to investing in the biotechnology sector. Out of the largest biotechnology stocks, only Amgen has made...
JNJ: 107.56 (-0.16), GILD: 101.82 (+0.94), AZN: 73.94 (+0.12), AMGN: 166.55 (-1.52)
A Practical Approach To Tech Investing
Franklin Templeton Investments - Seeking Alpha - Thu Dec 04, 8:00AM CST
Matt Moberg Vice President/Research Analyst Portfolio Manager, Franklin DynaTech Fund Franklin Equity Group® With the nervousness over geopolitical concerns, including a slowdown in the eurozone, ISIS in the Middle East and the US mid-term...
GILD: 101.82 (+0.94), FB: 75.24 (+0.36), BABA: 109.17 (-1.47)
Reveal Earnings Forecast for Gilead Sciences, Kinder Morgan, JD.Com, Sirius XM, Apple, and Plug Power
PR Newswire - Thu Dec 04, 7:45AM CST
EarningForecast.com has issued earnings forecast research with special focus on financial performance of the following stocks: Gilead Sciences (NASDAQ:GILD), Kinder Morgan (NYSE:KMI), JD.Com (NASDAQ:JD), Sirius XM (NASDAQ:SIRI), Apple (NASDAQ:AAPL), and Plug Power (NASDAQ
LUG). KMI: 41.46 (-0.37), GILD: 101.82 (+0.94), PLUG: 3.70 (+0.20), JD: 24.47 (-0.13), AAPL: 115.49 (-0.44), SIRI: 3.58 (-0.02)
U.S. Veterans get Sovaldi for $594/pill
Seeking Alpha - at Seeking Alpha - Thu Dec 04, 7:43AM CST
GILD: 101.82 (+0.94), ABBV: 69.57 (+1.07)
Johnson & Johnson Bought Alios for Hepatitis C
Cheryl Swanson, The Motley Fool - Motley Fool - Thu Dec 04, 7:21AM CST
Don't look now, but Johnson & Johnson last month bought up South San Francisco-based Alios BioPharma for a cool $1.75 billion . So what's afoot? What is the health care giant really after with this deal? Alios is a clinical stage...
JNJ: 107.56 (-0.16), GILD: 101.82 (+0.94)
Cramer's Mad Money - PVH Fits Well At A Discount (12/3/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Thu Dec 04, 5:04AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday December 3. CEO interview: Manny Chirico, PVH (NYSE: PVH ). Other stock mentioned: J.C. Penney (NYSE: JCP ) PVH ( PVH ) delivered an 8 cent earnings...
BIIB: 341.18 (-6.16), HON: 99.26 (-0.71), UTX: 111.21 (+0.22), KMB: 114.60 (-0.10), INTC: 37.46 (+0.03), PVH: 122.68 (-1.72), SLB: 87.43 (+0.67), PEP: 97.75 (-0.57), GWPH: 74.55 (-1.46), EOG: 93.00 (+1.20), REGN: 423.21 (-1.20), CSCO: 27.77 (-0.18), MU: 36.07 (-0.03), SWKS: 69.75 (+3.08), HAL: 40.74 (-0.01), SN: 9.06 (-0.88), BMY: 58.89 (-0.14), BA: 131.32 (-0.65), HPQ: 39.07 (+0.02), CELG: 113.63 (-0.60), ZTS: 44.00 (-0.88), GILD: 101.82 (+0.94), TXN: 55.41 (-0.21), JCP: 6.73 (-0.46), PG: 90.58 (+0.58), PAY: 35.96 (+0.15), SWHC: 9.41 (-0.10)
Jim Cramer's 'Mad Money' Recap: Cyclical Stocks Are Fund Manager Picks Now
at The Street - Wed Dec 03, 7:36PM CST
Staple stocks like PepsiCo and Procter & Gamble were leaders but now fund managers are turning to the Caterpillars and Cummins of the world, Cramer says.
HK: 1.80 (-0.25), MAIN: 31.89 (+0.17), INTC: 37.46 (+0.03), SLB: 87.43 (+0.67), PVH: 122.68 (-1.72), HUM: 141.12 (-0.59), PEP: 97.75 (-0.57), AGN: 213.71 (+1.74), ECA: 14.97 (-0.51), SCTY: 52.37 (+0.63), CMI: 149.96 (-0.64), GWPH: 74.55 (-1.46), EOG: 93.00 (+1.20), EMC: 30.32 (+0.01), GOOGL: 542.58 (+5.61), CAT: 99.67 (-0.51), ZNGA: 2.53 (-0.01), CSCO: 27.77 (-0.18), SD: 2.35 (-0.13), CBI: 46.07 (-1.33), JOY: 51.50 (-0.72), MU: 36.07 (-0.03), ETN: 69.48 (-0.73), HAL: 40.74 (-0.01), SN: 9.06 (-0.88), BMY: 58.89 (-0.14), HPQ: 39.07 (+0.02), CELG: 113.63 (-0.60), PXD: 145.53 (-5.20), GILD: 101.82 (+0.94), PG: 90.58 (+0.58), AUY: 4.01 (-0.10), SNDK: 102.64 (-0.72)
Third Quarter Earnings Season In Review: Sector Winners And Losers, The Misleading 'Record' Beat Rate And The Outlook For Q4
Leigh Drogen - Seeking Alpha - Wed Dec 03, 4:50PM CST
On Monday, the third quarter earnings season will officially close out, with H&R Block (NYSE: HRB ) as the final S&P 500 company to report. The season is ending with impressive earnings growth of 11.7%, paired with revenue growth of 4.8%,...
KO: 43.50 (-0.30), JNJ: 107.56 (-0.16), AA: 17.24 (+0.03), GE: 26.09 (-0.29), AZO: 588.07 (-2.48), NKE: 99.05 (+0.55), GILD: 101.82 (+0.94), MCD: 95.66 (+0.16), XOM: 94.37 (-0.58), DG: 67.79 (+1.10), PVH: 122.68 (-1.72), HRB: 34.14 (-0.33)
Actelion submits MAA for pulmonary hypertension drug
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 2:36PM CST
MSTX: 0.45 (-0.02), GILD: 101.82 (+0.94), UTHR: 129.05 (-3.30), GSK: 45.89 (-0.82), ARNA: 4.14 (-0.06)
Gilead Sciences' (GILD) Management Presents at Piper Jaffray Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Wed Dec 03, 10:53AM CST
GILD: 101.82 (+0.94)
Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/pbx995/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Idiopathic Pulmonary Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AdAlta - AnaptysBio - Auspex Pharmaceuticals - BiOrion Technologies - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgeneration - Chong Kun Dang Pharmaceutical - Compugen - Corridor Pharmaceuticals - F. Hoffmann-La Roche - FibroGen - GenKyoTex - Gilead Sciences - GlaxoSmithKline - HanAll Biopharma - Histocell - ImmuneWorks - IntelGenx - InterMune - Kasiak Research - LTT Bio-Pharma - Lanthio Pharma - MSM Protein Technologies - MedImmune - Moerae Matrix - Pacific Therapeutics - Pharmaxis Limited - ProMetic Life Sciences For more information visit http://www.researchandmarkets.com/research/pbx995/idiopathic
BIIB: 341.18 (-6.16), GILD: 101.82 (+0.94), CGEN: 7.40 (+0.56), ASPX: 24.53 (-0.43), GSK: 45.89 (-0.82), BMY: 58.89 (-0.14)
